Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Expert Review of Pharmacoeconomics & Outcomes Research|December 11, 2020
Economic analyses of immune-checkpoint inhibitors to treat lung cancerAlain Vergnenegre, Christos Chouaid
Pharmacoeconomics|March 4, 2009
Economics of treatments for non-small cell lung cancerChristos Chouaid, Kukovi Atsou, Gilles Hejblum, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 31, 2014
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewChristos Chouaïd, Perinne Crequit, Isabelle Borget, et al.
Translational Lung Cancer Research|March 26, 2015
Management of elderly patientsAlain Vergnenegre, Romain Corre, Hervé Lena, et al.
Translational Lung Cancer Research|March 26, 2015
How old is "too old" for translational research?Alain Vergnenegre, Romain Corre, Hervé Lena, et al.
Current Medical Research and Opinion|June 15, 2007
Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysisChristos Chouaid, Isabelle Monnet, Gilles Robinet, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|July 11, 2002
[Epidemiology of prostate cancer in the Limousin area]Michel Druet-Cabanac, Pierre Colombeau, Pierre-Marie Preux, et al.
Future Oncology (London, England)|January 3, 2020
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC<sup>‡</sup> 04-2017)Alain Vergnenegre, Isabelle Monnet, Acya Bizieux, et al.
BMC Cancer|July 24, 2012
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)Christos Chouaid, Hervé Le Caer, Chrystelle Locher, et al.
Targeted Oncology|June 19, 2017
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung CancerOlivier Bylicki, Nicolas Paleiron, Jacques Margery, et al.
Pageof 6